Andrew John Partridge

Andrew John Partridge is a declared insider at 2 companies (chief executive); the most frequent names are Turning Point Therapeutics, Inc. and GRAIL, Inc. In total, 6 filings cover trades dated from 13 July 2020 to 5 October 2026.

The open-market record consists of 3 sales worth €1.2M, with no purchase. Other entries cover 3 share grants. So far in 2026, the count stands at no purchases and 1 sale.

The record was last updated on 7 October 2026 with an open-market sale (€1.0M) in GRAIL, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.